BIO 2025 | Abzena

What do breakroom snacks, superpowers, and ADC innovation have in common? They all came up in my conversation at BIO 2025 with Petra Dieterich, DPhil, MBA, one of the scientific minds behind Abzena. 👩‍🔬

From preclinical complexity to GMP manufacturing, Petra shared what makes Abzena a force in the ADC space—and yes, we got her take on who has the better snacks: U.S. or UK.

Here’s a taste of the questions we asked:
🧪 What’s the most overlooked challenge in getting an ADC to GMP?
🧬 What’s the most exciting innovation you’re seeing in antibody-drug conjugates (ADCs) right now?
🌈 What’s one capability more companies should be using?